BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Biotech Support Group Release: New Hemoglobin Capture Reagent From Blood and Hemolyzed Serum With NuGel™ Matrix


2/22/2013 3:25:46 PM

PRLog (Press Release) - Feb. 22, 2013 - MONMOUTH JUNCTION, NJ- Biotech Support Group LLC has developed a new product for it’s line of NuGel™ affinity support and HemogloBind™ hemoglobin capture/depletion products. NuGel-HemogloBind™ is a hemoglobin capture reagent from blood and hemolyzed serum with NuGel™ matrix. NuGel-Hemoglobind™ is reengineered for increased stability. It is based on Hemoglobind™ ligand attached to NuGel™ silica covalently bound to elastomeric polyelectrolytes. Research by authors Blank et al cites how hemoglobin interfered with analyte detection of albumin, aspartate aminotransferase, direct bilirubin, total protein on the SMAC and creatinine. Intravascular hemolysis causing increased hemoglobin affects laboratory values. NuGel-Hemoglobind™ binds >95% of hemoglobin from blood and removes hemoglobin from any species including human, mouse, rat, sheep, bovine, goat etc. It also removes hemoglobin from organs and tissues. The flow through fractions(hemoglobin depleted) retain their enzymatic and biological activity. Compatible with LC-MS, activity-probe profiling and for proteomic analysis NuGel-Hemoglobind™ is developed specifically for hemoglobin removal from whole blood and hemolyzed serum for biomarker and drug discovery. It is supplied as a dry power which increases it’s shelf life and stability. The protocol is rapid, linearly scaleable up or down and is compatible with high throughput automation. NuGel-Hemoglobind™ product works similar to Hemoglobind™.

For more information, visit: http://www.biotechsupportgroup.com/node/357

About Biotech Support Group LLC

Biotech Support Group LLC is a leading provider of proteomics and genomics sample preparation products and enrichment reagent kits as well as integrated biotechnology services for life sciences research, biomarker and drug discovery. Its principal products include: AlbuSorb™ for albumin depletion, AlbuVoid™ for albumin depletion plus low abundance serum protein enrichment, Cleanascite™ for lipid adsorption and clarification, NuGel™ for passivated silica-based affinity chromatography, ProCipitate™ & ProPrep™ for nucleic acid isolation, and for depletion and purifying hemoglobin; HemoVoid™ for depletion from red blood cells and HemogloBind™ primarily for hemolyzed serum. Biotech Support Group LLC and ProFACT Proteomics Inc., are collaborating on the development of a functional proteomics separations platform used in biomarker and functional proteomic prospecting. For more information, go to: http://www.biotechsupportgroup.com

CONTACT:

Dr. Swapan Roy

Biotech Support Group

1 Deer Park Drive, Suite M,

Monmouth Junction, NJ 08852, USA

732-274-2866

sales@biotechsupportgroup.com

http://www.biotechsupportgroup.com

Suggested References

Blank, DavidW, M. H. Kroll, M. E. Ruddel, and R. J. Elin. "Hemoglobin interference from in vivo hemolysis." Clinical chemistry 31, no. 9 (1985): 1566-1569.

Related HemogloBind™ References

Suggested References

Blank, DavidW, M. H. Kroll, M. E. Ruddel, and R. J. Elin. "Hemoglobin interference from in vivo hemolysis." Clinical chemistry 31, no. 9 (1985): 1566-1569.

Related HemogloBind™ References

Red Cell Lysates

Kyoungsook Park, Christopher D. Saudek, and Gerald W. Hart Increased Expression of ß-N-Acetylglucosamindase (O-GlcNAcase) in Erythrocytes from Prediabetic and Diabetic Individuals.Diabetes.2010;59(7):1845-50.

Stored Blood Products

Delobel J., Rubin O., Prudent M., Crettaz D., Tissot J.-D., Lion N.(2010) Biomarker Analysis of Stored Blood Products: Emphasis on Pre-Analytical Issues. International Journal of Molecular Sciences. 11(11):4601-4617

Red Blood Cells

Alvarez-Llamas, G., de la Cuesta, F., Barderas, M. G., Darde, V. M., Zubiri, I., Caramelo, C., Vivanco, F. A novel methodology for the analysis of membrane and cytosolic sub-proteomes of erythrocytes by 2-DE.Electrophoresis.2009;30:4095-4108

Zihao Wang, Kyoungsook Park, Frank Comer1, Linda C. Hsieh-Wilson, Christopher D. Saudek, Gerald W. Hart. Site-Specific GlcNAcylation of Human Erythrocyte Proteins: Potential Biomarker(s) for Diabetes Mellitus. Diabetes.2008;58, 309-317.

Datta, Pradip. Effect of Hemolysis, High Bilirubin, Lipemia, Paraproteins, and System Factors on Therapeutic Drug Monitoring. Handbook of Drug Monitoring Methods.2008; 97-109.

Sarawathi,et al., Relative quantification of glycated Cu-Zn superoxide dismutase in erythrocytes by electrospray ionization mass spectrometry, Biochimica et Biophysica Acta. 1999.1426(3):483-90

Serum

Baion, C.M. & Ali, A.C.Evaluation Of HemogloBind™ For Removal Of O-Raffinose Crosslinked Hemoglobin (Hemolink™) From Serum, poster AACC Meeting 1997.

Photo: http://www.prlog.org/12085555/1



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES